Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
"I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, and this is just really a point in time that we have to get through."
While Abbott posted a top and bottom line beat for the second quarter, investors were disappointed that the company tightened its full-year earnings guidance. Shares were down more than 8% by close. Abbott is known for a variety of products and services in the healthcare field, including medical devices, diagnostics, nutritional products and generic pharmaceuticals. The company is currently facing a number of lawsuits related to its specialized infant formula, but it managed a major win in court late last year.
According to Ford, Abbott's diagnostics business in China was not as strong as expected. But he emphasized that the company saw improvement in the segment "everywhere else except China," pointing to growth in the U.S., Europe and Latin America.
While Ford said Abbott wants its diagnostic business in China to recover "as soon as possible," he conceded that it might not happen for a few quarters. He said his company has made management changes and meets "every single week with the diagnostic team." But it was more "prudent" to plan for a recovery in the fourth quarter rather than the third, he said.
Abbott is seeing strength in other areas, Ford said, including its medical devices arm. According to Ford, that business has seen double-digit growth for several quarters. He attributed some of the progress to a "very rich pipeline" of devices, including those that help treat diabetes and heart issues.
He also said Abbott's generic pharmaceutical business is doing well in emerging markets.
"We bring a very large portfolio to these markets that have great fundamentals — growing middle class, aging population, higher birth rates," he said. "And they're looking for companies like Abbott to bring high-quality health care innovations to the market."
Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.Disclaimer The CNBC Investing Club holds shares of Abbott Laboratories.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Countries push for last-minute deals as Thursday tariff deadline looms; Trump claims 'people love the tariffs'
A dizzying array of trade crosscurrents continued Tuesday with a push for last-minute deals, lingering fuzziness on previously announced trade commitments, and indications that a deal to delay tariffs on China is "close." It all comes as global importers brace for a first deadline coming Thursday morning, when Donald Trump promises to implement a central plank of his trade agenda in the form of a tiered approach to "reciprocal" tariffs from 10% to 50%. The president has repeatedly said he's full-speed ahead on his plans and that no delays are likely — even teasing on CNBC Tuesday morning that he probably won't run for president again but that he'd like to, in part because, in his view, "people love the tariffs." (Trump is, of course, barred by the Constitution from running for a third term, but he's often floated the idea.) Some countries clearly aren't big fans at the moment and find themselves on the outside looking in — particularly Switzerland and India. Those two nations face notably divergent situations right now, with the Swiss president announcing she is flying to Washington, D.C., today to try to find last-minute concessions to avert a 39% tariff on goods from her nation. India, meanwhile, has seen its chances of a deal dwindle, with top aides for Indian Prime Minister Narendra Modi also reportedly traveling this week — but to Moscow. Trump downplayed the chances of major concessions with Switzerland during his call with CNBC Tuesday morning and added regarding India that "we settled on 25% [tariffs], but I think I am going to raise that very substantially over the next 24 hours." Trump also weighed in Tuesday morning on talks with China. Markets are closely watching for any signs of an agreement to delay a tariff snapback scheduled for Aug. 12, with Trump saying, "We're getting very close to a deal." The president also added that new sector-specific tariffs on semiconductors and pharmaceuticals are likely and that at least those pharmaceutical tariffs could be announced "within the next week or so." Read more: What Trump's tariffs mean for the economy and your wallet New details for some nations — and a focus on India and Switzerland Meanwhile, there is also some new clarity on some technical details around how the new tariff landscape will likely work beginning at 12:01 a.m. ET on Thursday. US customs officials this week offered additional technical guidance in a new document about how it'll handle some tariff exemptions. The news there may give some select importers a short-term breather. But with a full tally, according to Bloomberg Economics, the average US tariff rate is now expected to rise to 15.2% if duties go forward as planned. That's a jump from current rates of 13.3% and another jump from the 2.3% duties seen in 2024 before Trump took office. That overall landscape set to be in effect Thursday will cover nearly every country on the globe. It also comes after Trump and his team set "bespoke" rates largely based on the trade deficit, with many of America's top trading partners seeing a key new standard of 15% tariff, while others will see higher rates. Read more: 5 ways to tariff-proof your finances Countries from the European Union to South Korea to Japan also struck deals at that 15% rate, but open questions remain. Japan's top trade negotiator is also reportedly due in Washington, D.C., this week for talks to ensure that a plan proceeds to cut auto tariffs to 15%. Likewise, talks with the EU continue as negotiators there are reportedly still pushing for exemptions, such as on wine and spirits. Other Asian countries have struck deals in the 19%-20% range. Trade Representative Jamieson Greer recently said on CBS that the published rates included many agreements, "some of these deals are announced, some are not," with other nations simply being dictated tariffs based on the level of the trade deficit. Switzerland is one nation for which the US has dictated tariffs. Its delegation will be in Washington on Tuesday, set to push for lower rates. But on Tuesday morning, Trump suggested that it would be an uphill climb and that a recent call with the country didn't go well because "they essentially pay no tariffs," even as talks are clearly set to continue there. Meanwhile, any immediate offramp with India appears unlikely because of that nation's connections with Russia and Russian oil. A note Tuesday from Capital Economics suggested that India could, in theory, offer concessions to diversify its energy sources, "but we doubt that India would make a wholehearted effort to wean itself off Russian oil [as it could upset relations and] it would not play well to be seen caving to Trump's demands." At the same time, reports from Bloomberg and the Times of India revealed that two top aides to Indian Prime Minister Narendra Modi are traveling not to the US but to Russia in the coming days and weeks, even amid Trump's ever-escalating threats. Trump on Tuesday morning suggested talks are on ice for now and will be complicated when they resume, adding that "the sticking point with India is that tariffs are too high." Ben Werschkul is a Washington correspondent for Yahoo Finance. Click here for political news related to business and money policies that will shape tomorrow's stock prices Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
7 minutes ago
- Yahoo
US to initially impose 'small tariff' on pharma imports, Trump says
By Patrick Wingrove and Andrea Shalal WASHINGTON (Reuters) -President Donald Trump said on Tuesday that the United States would initially place a "small tariff" on pharmaceutical imports before hiking it to 150% within 18 months and eventually to 250% in an effort to boost domestic production. "In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," Trump told CNBC in an interview. He did not specify the initial tariff rate on pharmaceuticals. Trump said earlier this month that pharmaceutical tariffs could reach as high as 200%. Trump also said he plans to announce tariffs on semiconductors and chips in the "next week or so," but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15%.
Bloomberg
10 minutes ago
- Bloomberg
Two Former Treasury Secretaries Issue Warning on Risks to US Treasuries
The two US Treasury chiefs in office during the global financial crisis warned about potential threats to the $29 trillion Treasuries market ranging from an unsustainable fiscal path to concerns about the political system in Washington. 'Our current trajectory is unsustainable' with regard to federal borrowing, former Treasury Secretary Henry Paulson said in an interview on CNBC Tuesday. 'I don't know whether that means you hit the wall, you know, in six months or six years, or whatever.'
